Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib
Yingmiao Liu(Duke Medical Center), Andrew B. Nixon(Duke University), Anastasia Ivanova(University of North Carolina at Chapel Hill), Federica Marmorino(University of Pisa), Kouros Owzar(Duke University), Kelli Hammond(University of North Carolina at Chapel Hill), Federico Innocenti(AbbVie (United States)), Mark D. Starr(Duke Medical Center), Jing Lyu(University College Dublin), Kirsten B. Burdett(Northwestern University), Richard M. Goldberg(Ontario Institute for Cancer Research), Chiara Cremolini(University of Pisa), Ace J. Hatch(Duke Medical Center), Hanna K. Sanoff(University of North Carolina at Chapel Hill), Michael S. Lee(Duke Medical Center), John C. Brady(Duke Medical Center), Alfredo Falcone(Azienda Ospedaliero-Universitaria Careggi), Dominic T. Moore(University of North Carolina at Chapel Hill), Alexander B. Sibley(Duke University)
Cited by 30
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest
|Journal of Clinical Oncology|2007|1.2k